Tagomago schreef op 27 januari 2016 15:22:
Galapagos (NASDAQ:GLPG) - Yet another NASDAQ-listed Belgian biotech with a strong pipeline of mid-stage products, which recently achieved key stages of their development program (successful Phase 2b results in RA and Crohn's disease). Filgotinib, the biotech's most advanced product, is an oral JAK1-inhibitor initially partnered with Abbvie - the big pharma walked away from its deal in 2015 to favor a similar internally developed compound, only to be replaced a few months laters by Gilead (NASDAQ:GILD) in an even bigger $2.1 billion deal. Currently sitting on a big pile of cash (over $600 million)
thanks to its latest deals, the biotech is properly tooled to execute its development plans over the next years without worrying too much about market conditions - a strong fundamental perspective that should be supported by a nice series of catalysts in early 2016, such as several Phase 1 and Phase 2 clinical results (including 20-week results in Crohn's disease and early data in idiopathic pulmonary disease and cystic fibrosis) and the initiation of a large Phase 3 trial in RA.